Dopamine agonists for preventing ovarian hyperstimulation syndrome

CONCLUSIONS: Dopamine agonists probably reduce the incidence of moderate or severe OHSS compared to placebo/no intervention, while we are uncertain of the effect on adverse events and pregnancy outcomes (live birth, clinical pregnancy, miscarriage). Dopamine agonists plus co-intervention may decrease moderate or severe OHSS rates compared to co-intervention only, but we are uncertain whether dopamine agonists affect pregnancy outcomes. When compared to other active interventions, we are uncertain of the effects of dopamine agonists on moderate or severe OHSS and pregnancy outcomes.PMID:33851429 | DOI:10.1002/14651858.CD008605.pub4

Source: Cochrane Database of Systematic Reviews - April 14, 2021 Category: General Medicine Authors: Huilin Tang Selma M Mourad Aihua Wang Suo-Di Zhai Roger J Hart Source Type: research